Dr. Cartier Esham's Testimony at the Senate Committee on Health, Education, Labor & Pensions Hearing

Highlights of BIO’s Chief Scientific Officer, Dr. Cartier Esham’s testimony at the U.S. Senate Committee on Health, Education, Labor and Pensions Hearing, “FDA User Fee Agreements: Advancing Medical Product Regulation and Innovation for the Benefit of Patients,” on April 5, 2022.

source